Logo
x

Search

Subscribe Now

Immunocore

Immunocore Partners with BMS to Develop IMC-F106C in the P-III (PRISM-MEL301) Trial for the Treatment of Melanoma

Immunocore Partners with BMS to Develop IMC-F106C in the P-III (PRISM-MEL301) Trial for the Treatment of Melanoma

  • February 23, 2024
Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada

Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Au...

  • June 9, 2022
Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

  • April 5, 2022
PharmaShots Weekly Snapshots (February 21-25, 2022)

PharmaShots Weekly Snapshots (February 21-25, 2022)

  • February 25, 2022
Immunocore Receives EMA’s CHMP Positive Opinion for Kimmtrak (tebentafusp) to Treat Unresectable or Metastatic Uveal Melanoma

Immunocore Receives EMA’s CHMP Positive Opinion for Kimmtrak (tebentafusp) to Treat Unresectable or Metastatic Uveal Melanoma

  • February 25, 2022
Immunocore’s Kimmtrak (tebentafusp-tebn) Receives the US FDA’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore’s Kimmtrak (tebentafusp-tebn) Receives the US FDA’s Approval for the Treatment of Unresectable or Metastatic Uveal Mela...

  • January 27, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.